MacroGenics Valuation
| MGNX Stock | USD 2.54 0.11 4.15% |
Based on Macroaxis valuation methodology, the firm appears to be overvalued. MacroGenics secures a last-minute Real Value of $2.35 per share. The latest price of the firm is $2.54. Our model forecasts the value of MacroGenics from analyzing the firm fundamentals such as Return On Equity of -0.62, current valuation of 60.14 K, and Profit Margin of (0.69) % as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that MacroGenics' price fluctuation is very risky at this time. Calculation of the real value of MacroGenics is based on 3 months time horizon. Increasing MacroGenics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since MacroGenics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of MacroGenics Stock. However, MacroGenics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.54 | Real 2.35 | Hype 2.54 | Naive 2.91 |
The intrinsic value of MacroGenics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence MacroGenics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of MacroGenics helps investors to forecast how MacroGenics stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of MacroGenics more accurately as focusing exclusively on MacroGenics' fundamentals will not take into account other important factors: MacroGenics Total Value Analysis
MacroGenics is now estimated to have valuation of 60.14 K with market capitalization of 166.32 M, debt of 33.97 M, and cash on hands of 133.74 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the MacroGenics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
60.14 K | 166.32 M | 33.97 M | 133.74 M |
MacroGenics Investor Information
About 94.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.44. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. MacroGenics has Price/Earnings To Growth (PEG) ratio of 0.01. The entity recorded a loss per share of 1.57. The firm had not issued any dividends in recent years. Based on the key indicators related to MacroGenics' liquidity, profitability, solvency, and operating efficiency, MacroGenics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.MacroGenics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. MacroGenics has an asset utilization ratio of 19.69 percent. This suggests that the Company is making $0.2 for each dollar of assets. An increasing asset utilization means that MacroGenics is more efficient with each dollar of assets it utilizes for everyday operations.MacroGenics Ownership Allocation
MacroGenics maintains a total of 62.76 Million outstanding shares. The majority of MacroGenics outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in MacroGenics to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in MacroGenics. Please pay attention to any change in the institutional holdings of MacroGenics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.MacroGenics Profitability Analysis
The company reported the previous year's revenue of 58.75 M. Net Loss for the year was (9.06 M) with loss before overhead, payroll, taxes, and interest of (51.3 M).About MacroGenics Valuation
Our relative valuation model uses a comparative analysis of MacroGenics. We calculate exposure to MacroGenics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of MacroGenics's related companies.MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. The company was incorporated in 2000 and is headquartered in Rockville, Maryland. Macrogenics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 427 people.
MacroGenics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 61.9 M | |
| Quarterly Earnings Growth Y O Y | 2.205 |
Additional Tools for MacroGenics Stock Analysis
When running MacroGenics' price analysis, check to measure MacroGenics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MacroGenics is operating at the current time. Most of MacroGenics' value examination focuses on studying past and present price action to predict the probability of MacroGenics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MacroGenics' price. Additionally, you may evaluate how the addition of MacroGenics to your portfolios can decrease your overall portfolio volatility.